Yasmin

Low-dose monophasic oral contraceptive with antiMKS and antiandrogenic effects. The contraceptive effect is due to several factors, most important of which is inhibition of ovulation and change the viscosity of cervical mucus. Endometrium remains unprepared for the implantation of the egg. As a result of increasing the viscosity of cervical mucus penetration of sperm cells is hampered in the uterine cavity. Drospirenone has antiMKS activity that can prevent weight gain and other symptoms associated with fluid retention (delay prevents Na, caused by estrogen provides a very good tolerability and positive impact in premenstrual syndrome).

In combination with ethinylestradiol improves the lipid profile and increases the concentration of HDL. Has anti-androgenic activity, which leads to a decrease acne formation and reduced production of the sebaceous glands, has no effect on ethinylestradiol induced increase in education globulin, sex hormone binding (inactivation of endogenous androgens). Drospirenone devoid of any androgenic, estrogenic, SCS and antiGKS activity.

This, coupled with antiMKS and antiandrogenic effects, drospirenone provides biochemical and pharmacological profile similar to natural progesterone. As with all combined oral contraceptives has a positive effect Noncontraceptive: menstrual bleeding becomes lighter and shorter, which reduces the risk of anemia, pain - less pronounced or disappear completely.